Table 1.
Means, standard deviations, and frequencies of demographic, medical, and treatment variables by study group; ER=estrogen receptor; PR=progesterone receptor; HER2/neu=human epidermal growth factor.
| Variable | n | Total | Control | Intervention | p |
|---|---|---|---|---|---|
| Age at diagnosis (years) | 51 | 49.67 (7.15) | 50.83 (6.84) | 48.71 (7.37) | 0.298 |
| Race/ethnicity | 51 | 0.645 | |||
| White non-Hispanic | 39 (76.5%) | 19 (82.6%) | 20 (71.4%) | ||
| Hispanic | 6 (11.8%) | 2 (8.7%) | 4 (14.3%) | ||
| African American | 6 (11.8%) | 2 (8.7%) | 4 (14.3%) | ||
| Employment Status | 51 | 0.258 | |||
| Not employed | 6 (11.8%) | 4 (17.4%) | 2 (7.1%) | ||
| Employed | 45 (88.2%) | 19 (82.6%) | 26 (92.9%) | ||
| Education (years) | 51 | 15.61 (2.50) | 15.22 (2.59) | 15.93 (2.42) | 0.317 |
| Income (thousands of dollars) | 78.16 (53.56) | 80.48 (71.23) | 76.04 (31.35) | 0.788 | |
| Menopausal status | 51 | 0.683 | |||
| Premenopausal | 26 (51.0%) | 11 (47.8%) | 15 (52.6%) | ||
| Postmenopausal | 25 (49.0%) | 12 (52.2%) | 13 (46.4%) | ||
| Stage | 51 | 0.538 | |||
| 0 | 10 (19.6%) | 4 (17.4%) | 6 (21.4%) | ||
| I | 22 (43.1%) | 10 (43.5%) | 12 (42.9%) | ||
| II | 17 (33.3%) | 9 (39.1%) | 8 (28.6%) | ||
| III | 2 (3.9%) | 0 (0.0%) | 2 (7.1%) | ||
| Positive lymph nodes | 51 | 0.90 (3.02) | 0.17 (4.91) | 1.5 (3.99) | 0.120 |
| Size of tumor (cm) | 23 | 2.07 (1.29) | 2.12 (1.09) | 1.02 (1.47) | 0.864 |
| ER status | 43 | 0.841 | |||
| Positive | 38 (88.4%) | 17 (89.5%) | 21 (87.5%) | ||
| Negative | 5 (11.6%) | 2 (10.5%) | 3 (12.5%) | ||
| PR status | 36 | 0.498 | |||
| Positive | 26 (72.2%) | 11 (78.6%) | 15 (68.2%) | ||
| Negative | 10 (27.8%) | 3 (21.4%) | 7 (31.8%) | ||
| HER2/neu status | 24 | 0.324 | |||
| Positive | 7 (29.2%) | 4 (40.0%) | 3 (21.4%) | ||
| Negative | 17 (70.8%) | 6 (60.0%) | 11 (78.6%) | ||
| Procedure type | 51 | 0.357 | |||
| Lumpectomy | 23 (45.1%) | 12 (52.2%) | 11 (39.3%) | ||
| Mastectomy | 28 (54.9%) | 11 (47.8%) | 17 (60.7%) | ||
| Received chemotherapy | 50 | 0.854 | |||
| Yes | 28 (56.0%) | 12 (54.6%) | 16 (57.1%) | ||
| No | 22 (44.0%) | 10 (45.5%) | 12 (42.9%) | ||
| Received radiation therapy | 48 | 0.096 | |||
| Yes | 26 (54.2%) | 8 (40.0%) | 18 (64.3%) | ||
| No | 22 (45.8%) | 12 (60.0%) | 10 (35.7%) | ||
| Received endocrine therapy | 50 | 0.852 | |||
| Yes | 38 (76.0%) | 17 (77.3%) | 21 (75.0%) | ||
| No | 12 (24.0%) | 5 (22.7%) | 7 (25.0%) | ||
Note. Means, standard deviations, and frequencies of demographic, medical, and treatment variables by study group; ER=estrogen receptor; PR=progesterone receptor; HER2/neu=human epidermal growth factor.